Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures

Table 5 Experimentally validated target genes for miRNAs

miRNA	Target gene	Regulation	Validation method	Cancer	Reference
hsa-miR-222	GJA1	down	Immunofluorescence, Western Blot, Luciferase Reporter Assay	Glioblastoma	[35]
	CDKN1C	down	Luciferase Reporter Assay	Glioblastoma	[69]
	P27kip1	down	Western Blot	Glioblastoma	[32]
	DICER1	down	Luciferase Reporter Assay	Breast cancer	[70]
	TIMP3	Down	Luciferase Reporter Assay, qPCR, Western Blot	Lung cancer	[36]
	CDKN1B	Down	Luciferase Reporter Assay	Thyroid carcinoma	[71]
	PPP2R2A	Down	Luciferase Reporter Assay	Lung cancer	[72]
hsa-miR-345	MCL-1 and BCL2L2	Up	microarray	Lung cancer	[73]
	Smad1	Down	microarray	Prostate cancer	[39]
	BAG3	Down	Luciferase reporter assay and western blot	colorectal cancer	[40]
hsa-miR-335	SOX4	Down	Northern blot, qRT-PCR etc.	breast cancer	[74]
hsa-miR-335	TGF-β	Down	qRT-PCR	Neuroblastoma	[44]
hsa-miR-122a	CCNG1	Down	Northern blot, qRT-PCR	hepatocellular carcinoma	[75]
hsa-miR-24	ST7L	Up	qRT-PCR	glioma	[45]
hsa-miR-24	MXI1	Up	MTT assay	glioma	[46]
hsa-miR-433	FGF20	-	- Northern blot, qRT-PCR etc.	Parkinson’s disease	[76]
hsa-miR-320	TfR-1	Down	northern blot, qRT-PCR	acute myeloid leukemia	[77]
hsa-miR-320	Mcl-1, BCL2	Down	northern blot, qRT-PCR	cholangiocarcinoma	[78]

ISSN: 1471-2164